Therapeutic Areas

November 20th 2024

Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.

November 19th 2024

The Phase III CLEAR SYNERGY trial found that long-term colchicine treatment after acute myocardial infarction does not reduce major cardiovascular events compared to placebo, highlighting mixed results from prior studies on its efficacy in cardiovascular disease.

November 18th 2024

The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.

November 15th 2024

Multiple Phase III trials and open label extensions show Bimzelx (bimekizumab-bkzx) offers an effective approach in targeting key inflammatory pathways involved in psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.